Jump to content

Caffeine: Difference between revisions

From Pharmacopedia
[pending revision][pending revision]
Recategorize: Stimulants & Wake-Promoting Agents -> Stimulants
Recategorize: Stimulants -> Psychostimulants
 
Line 38: Line 38:
}}
}}


[[Category:Stimulants]]
[[Category:Psychostimulants]]
[[Category:Xanthines]]
[[Category:Xanthines]]
[[Category:Psychostimulants]]
[[Category:Psychostimulants]]

Latest revision as of 10:50, 17 May 2026

Xanthine, Stimulant
Caffeine

Experience

👥 No personal reports yet
No clinical reports yet

Log in to add your own experience.

Problems

No problems yet. Be the first to suggest one.

+ Add a problem

Titration strategies

No titration strategies yet. Be the first to suggest one.

+ Add a titration strategy

Effects

No effects listed yet. Be the first to suggest one.

+ Add an effect

Interactions

Pharmacogenomic + mechanism interactions2 edges
Pharmacokinetic mechanismSubstrate / metabolism relationships from primary literature
Enzyme:CYP1A2 substrate major Primary 80 / 100
FDA Drug Interactions Table: sensitive index substrate of CYP1A2.
Inferred from pharmacokinetic dataMaterialised by the inference engine; provenance shown per row
Fluvoxamine pk raises via CYP1A2 Inferred 72 / 100
Fluvoxamine inhibits CYP1A2 (inhibitor_strong, intensity 90); Caffeine is a substrate_major of CYP1A2 (intensity 80). Derived: Caffeine exposure raised.
Inferred via Enzyme:CYP1A2 (exposure raised)

Patient experience

No patient-experience reports yet.

Relevant anecdote

No anecdotes yet. Share a relevant one.

+ Add an anecdote

Relevant Literature

No literature entries yet.

Log in to submit relevant literature.

Summary
Classes
Xanthine, Stimulant
Pharmacy
Pharmacology
Purported mechanism
Adenosine receptor antagonist


Pendell's corner
Caffeine is a central nervous system stimulant, a cardiac stimulant, a respiratory stimulant, and a diuretic. Caffeine is addictive. Withdrawal symptoms typically include irritability, fatigue, and headaches, sometimes severe.
— Dale Pendell, Pharmako/Dynamis, p. 29